Immunogenicity and duration of antibodies after vaccination with a two-dose series of the nine-valent human papillomavirus vaccine among Alaska Native children: a prospective cohort study

Immunogenicity and duration of antibodies after vaccination with a two-dose series of the nine-valent human papillomavirus vaccine among Alaska Native children: a prospective cohort study

Abstract Background Human papillomavirus (HPV)-associated cancers are vaccine preventable. In 2016, the previously recommended three-dose HPV vaccination series was changed to a two-dose series and nine-valent HPV vaccine (9vHPV) became the only HPV vaccine available in the United States. Data on lo...

Full description

Saved in:
Bibliographic Details
Main Authors: Jonathan Steinberg, Gitika Panicker, Elizabeth R. Unger, Ian Blake, Rayleen M. Lewis, Jesse Geis, Dana Bruden, Marc Fischer, Lauri E. Markowitz, Michael G. Bruce
Format: Article
Language:English
Published: BMC 2025-04-01
Series:BMC Infectious Diseases
Subjects:
Human papillomavirus viruses
Vaccines
Alaska
Online Access:https://doi.org/10.1186/s12879-025-10961-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items